眼科

• 论著 • 上一篇    下一篇

糖皮质激素不同给药方式治疗中重度甲状腺相关性眼病的Meta分析

周立萍  李佳  刘明明  袁洪峰   

  1. 400042重庆市,解放军陆军军医大学第三附属医院(野战外科研究所)眼科 重庆市眼科学重点实验室
        
  • 收稿日期:2017-07-22 出版日期:2018-07-25 发布日期:2018-07-27
  • 通讯作者: 袁洪峰,Email:yhf871@sina.cn

Meta analysis of the glucocorticoid of different administration methods for moderate and severe thyroid-associated ophthalmopathy 

ZHOU Li-ping, LI Jia, LIU Ming-ming, YUAN Hong-feng.   

  1. Department of Ophthalmology, Institute of Surgery Research, Daping Hospital, Army Medical University; Chongqing Key Laboratory of Ophthalmology, Chongqing 400042, China
  • Received:2017-07-22 Online:2018-07-25 Published:2018-07-27
  • Contact: YUAN Hong-feng, Email: yhf871@sina.cn

摘要:

目的 系统评价糖皮质激素不同给药方式治疗中重度甲状腺相关性眼病的有效性和安全性。设计 系统评价。研究对象 以糖皮质激素治疗的中重度甲状腺相关性眼病患者的中英文文献。方法 计算机检索PubMed、EMBase、The Cochrane Library、中国生物医学文献数据库(CBM)、中国知网(CNKI)、维普网(VIP)和万方数据库。搜集糖皮质激素不同给药方式治疗中重度甲状腺相关性眼病的随机对照试验,检索自建库截止至2017年6月。由2位研究人员独立进行文献筛选、数据提取和质量评价后,采用RevMan5.3软件进行Meta分析。主要指标 治疗有效率和CAS评分。结果 共纳入12个随机对照试验,包括589例患者。静脉给药组与口服给药组相比治疗有效率[RR=1.38,95%CI(1.19,1.60),P<0.0001]更高、CAS评分改善情况[MD=0.84,95%CI(0.32,1.36),P=0.002]、生活质量改善情况[MD=1.22,95%CI(1.04,1.44),P=0.01]更好,差异具有统计学意义;球后注射给药组与口服给药组相比突眼改善情况[MD=1.01,95%CI (0.83,1.20),P<0.00001)更好;静脉给药组与球后注射给药组相比突眼改善情况[MD=-3.60,95%CI (-4.93,-2.27), P<0.00001)更差、睑裂宽度改善情况[MD=-3.57, 95%CI (-4.84, -2.30),P<0.00001)更差;静脉给药组相比口服给药组在高血压[RR=0.26,95%CI (0.08,0.87),P=0.03]、体重增加[RR=0.27, 95%CI (0.11,0.70),P=0.007]、库欣综合征[RR=0.23,95%CI (0.12,0.44),P<0.0001)等不良反应发生率更低,差异具有统计学意义。结论 当前证据表明,糖皮质激素静脉给药在甲状腺相关性眼病治疗有效率、CAS评分改善情况、生活质量改善情况以及减少不良反应出现等方面有较为出色的效果,球后注射改善突眼情况效果更突出。此结论尚需大样本高质量临床研究予以证实。(眼科, 2018, 27: 269-275)

关键词: 糖皮质激素, 给药方式, 甲状腺相关性眼病, Meta分析

Abstract:

 Objective To systematically review the effectiveness and safety of different glucocorticoid administration methods in the treatment of thyroid-associated ophthalmopathy (TAO). Design Systematic review. Participants Published articles associated with corticosteroids therapy for moderate to severe TAO. Methods Databases including PubMed, EMBase, The Cochrane Library (Issue 6, 2017), CBM, CNKI, VIP and Wan Fang Data were searched to collect randomized controlled trials (RCTs) about the effectiveness and safety of different glucocorticoid administration methods in the treatment of TAO from inception to June 2017. Two reviewers independently screened literatures, extracted data and assessed the quality of included studies. Then meta-analysis was conducted by RevMan 5.3 software. Main Outcome Measures Effective rate and CAS score. Results A total of 12 studies involving 589 patients were included. The results of meta-analysis showed that: compared with the oral administration group, effective rate of intravenous administration group was higher[RR=1.38, 95%CI (1.19, 1.60), P<0.0001], the CAS score improved better[MD=0.84, 95%CI (0.32, 1.36), P=0.002], the quality of life improved better [MD=1.22, 95%CI (1.04, 1.44), P=0.01], the improvement of the exophthalmos of the retrobular injection group was higher than oral administration group[MD=1.01, 95%CI (0.83, 1.20), P<0.00001]. Compared with the intravenous administration group, the improvement of the exophthalmos of the retrobular injection group was higher [MD=-3.60, 95%CI (-4.93, -2.27), P<0.00001], improvement of palpebral fissure width was higher[MD=-3.57, 95%CI (-4.84, -2.30), P<0.00001]. Compared with the intravenous administration group, the incidence rate of adverse reactions such as hypertension [RR=0.26, 95%CI (0.08, 0.87), P=0.03], weight gain [RR=0.27, 95%CI (0.11, 0.70), P=0.007] and Cushing syndrome [RR=0.23, 95%CI (0.12, 0.44), P<0.0001] in the oral administration group was higher, and the difference was statistically significant. Conclusion Current evidence shows that intravenous administration has a more potent effect on TAO treatment efficiency, CAS score improvement, improvement in quality of life, and reduction of adverse events and posterior balloon injection is more effective in improving exophthalmos. Due to the limited quality of included studies, the above conclusion still needs to be verified by more high quality studies. (Ophthalmol CHN, 2018, 27: 269-275)

Key words: glucocorticoids, mode of administration, thyroid-associated ophthalmopathy, Meta-analysis